Introduction
Lung cancer is the most common malignant disease worldwide and is the major cause of death from cancer. Although tobacco smoking is the overwhelming cause of lung cancer, vehicular exhaust and ambient air pollution are also implicated as causative factors [1] [2] [3] [4] . Nitro-aromatic compounds are widely distributed environmental pollutants found in exhaust from diesel and gasoline engines and on the surface of ambient air particulate matter. The increased lung cancer risk after exposure to these environmental sources and the detection of nitro-aromatics in the lungs of non-smokers with lung cancer has led to considerable interest in assessing their potential cancer risk [1] [2] [3] [4] .
The nitroaromatic 3-nitrobenzanthrone (3-nitro-7H-benz [de] anthracen-7-one, 3-NBA) ( Fig. 1) occurs in diesel exhaust and in airborne particulate matter [5] [6] [7] [8] . The main metabolite of 3-NBA, 3-aminobenzanthrone (3-ABA) (Fig. 1 ) [9, 10] , has been found in urine samples of salt mine workers occupationally exposed to diesel emissions [6] , demonstrating human exposure to 3-NBA. 3-NBA is carcinogenic in rats, causing lung tumours after intratracheal instillation [7] . It is also an exceptionally potent mutagen in the Ames Salmonella typhimurium assay, scoring more than 6 million revertants per nanomole in strain YG1024 overexpressing bacterial nitroreductase and Oacetyltransferase [5] . 3-NBA has also been shown to be genotoxic in several other short-term tests and in the transgenic Muta Mouse assay [11, 12] . Its genotoxicity has been further documented by the detection of specific DNA adducts formed in vitro as well as in vivo in rodents in various tissues [11, 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] .
In liver, lung and kidney most of the metabolic activation of 3-NBA is attributable to cytosolic human and rat NAD(P)H:quinone oxidoreductase (NQO1). Human N,O-acetyltransferase (NAT), NAT2, followed by NAT1, sulfotransferase (SULT), SULT1A1 and, to a lesser extent, SULT1A2
are the major activating phase II enzymes [10, 18, 23, 24] . Human hepatic NADPH:cytochrome P450 (CYP) reductase also effectively activates 3-NBA [17] , but in mice, 3-NBA is predominantly activated by NQO1 rather than NADPH:CYP reductase [18] (Fig. 1 ).
CYP1A1 and 1A2 (CYP1A1/2) are essential for the oxidative activation of 3-ABA in human and rat livers forming the same DNA adducts that are formed in vivo by 3-ABA or 3-NBA [25, 26] .
However, other organs also have the metabolic capacity to activate 3-ABA to form DNA adducts, independent from the CYP-mediated oxidation in the liver [27] . Previous results indicate that besides CYP enzymes expressed in several extra-hepatic tissues, peroxidases may play a role in the oxidative activation of 3-ABA [27] . Mammalian prostaglandin H synthase (cyclooxygenase, COX), lactoperoxidase (LPO) and myeloperoxidase (MPO) were found to be effective in activating 3-ABA [27] (Fig. 1) . In animal experiments with Wistar rats the major role of CYP1A1 in 3-ABA activation in lungs and kidneys rather than peroxidases was elucidated [24, 28] . In the same rat model we treated rats with single i.p. doses of 0.4, 4 or 40 mg/kg body weight (bw) of 3-NBA and saw that 3-NBA induces the major enzymes activating itself and its metabolite 3-ABA in livers [23] , lungs and kidneys [24] , thereby enhancing its own genotoxic and carcinogenic potential. Since inhalation is the major route by which airborne materials gain access to the body, primary exposure of the lungs to 3-NBA would constitute a better model system. However, experimental inhalation systems, with appropriate generation and characterization of exposure atmospheres, are expensive to acquire and maintain [29] . Therefore, direct instillation of a test material into the lungs via the trachea has been employed in many studies as an alternative exposure to inhalation. Instillation has also certain advantages over inhalation, the foremost being that the actual dose delivered to the lungs of each animal can be defined accurately.
Therefore, the objective of the present study was to evaluate whether the major enzymes activating 3-NBA (NQO1) and 3-ABA (CYP1A) are induced after a single intratracheal instillation of 3-NBA in the lungs, livers and kidneys of rats and if so, whether this induction also leads to higher DNA adduct levels, when cytosols and microsomes from these organs are incubated with 3-NBA and 3-ABA. The organs used in this study were from rats treated in an experiment to determine the persistence of 3-NBA-derived DNA adducts in target and non-target tissues [21, 22] .
Material and Methods

Chemicals
NADPH, deoxyadenosine (dA) 3'-monophospate, deoxyguanosine (dG) 3'-monophosphate, menadione (2-methyl-1,4-naphthoquinone) and calf thymus DNA were from Sigma Chemical Co (St Louis, MO, USA); 7-ethoxyresorufin and 7-methoxyresorufin from Fluka Chemie AG (Buchs, Switzerland). Enzymes and chemicals for the 32 P-postlabeling assay were obtained from sources described [30] . All these and other chemicals were reagent grade or better.
Synthesis of 3-NBA and 3-ABA
3-NBA and 3-ABA were synthesized as described [15] and their authenticity was confirmed by UV spectroscopy, electrospray mass spectra and high field proton NMR spectroscopy.
Animal experiments
The study was conducted in accordance with the German Regulations for the Care and Use of 
Preparation of microsomal and cytosolic fractions
Microsomal and cytosolic fractions were isolated from the livers, lungs and kidneys of rats, as described [31, 32] . Both subcellular preparations were analyzed for the presence of 3-NBA by HPLC on a CC 250/4 Nucleosil, 100-5 C18 HD column (Macherey-Nagel, 4 x 250 mm) preceded by a C-18 guard column. Eluent was 70% methanol in water, at a flow rate of 0.6 ml min NBA was detectable in microsomal and cytosolic fractions from rats that had been treated with this compound (data not shown).
Cytosolic incubations
The Control incubations were carried out either (i) without activating system (cytosol), (ii) without NADPH, (iii) without DNA or (iv) without 3-NBA. After extraction with ethyl acetate, DNA was isolated from the residual water phase by the phenol/chloroform extraction method as described
[18].
Microsomal incubations
Incubation mixtures, in a final volume of 750 µl, consisted of 50 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH, hepatic, pulmonary and renal microsomal samples from 3 rats (pooled samples), either control or treated with 0.2 or 2 mg/kg bw of 3-NBA (0.5 mg of microsomal protein), 100 µM 3-ABA or 3-NBA (dissolved in 7.5 µl dimethylsulfoxide) and 0.5 mg of calf thymus DNA. The reaction was initiated by adding 3-ABA or 3-NBA and were carried out at 37°C for 2 hr; the microsomal-mediated 3-NBA (3-ABA)-derived DNA adduct formation was found to be linear up to 3 hr [17, 25] . Control incubations were carried out either (i) without activating system (microsomes), (ii) with activating system and 3-ABA or 3-NBA, but without DNA or (iii) with activating system and DNA but without 3-ABA or 3-NBA. After the incubation and extraction with ethyl acetate, DNA was isolated from the residual water phase by the phenol/chloroform extraction method as described [25] .
32 P-Postlabeling analysis
32
P-Postlabeling analysis using butanol extraction, and thin layer chromatography (TLC) and HPLC were performed as described [19] . Enrichment by butanol extraction has been shown to yield more adduct spots and a better recovery of 3-NBA (3-ABA)-derived DNA adducts than using enrichment by nuclease P1 digestion [15, 19] . DNA adduct spots were numbered as reported [15, 19] . As reference compounds deoxyadenosine (dAp) and deoxyguanosine (dGp) 3'-monophosphates (4 µmol/ml) (Sigma) were incubated with 3-NBA (300 µM) activated by XO (1 U/ml) (Sigma) in the presence of hypoxanthine and analyzed as described [13] . DNA adduct
were prepared by reacting N-acetoxy-3-aminobenzanthrone with dAp or dGp and analysed as
Isolation of CYP1A1 and CYP1A2
Recombinant rat CYP1A1 protein was purified to homogeneity from membranes of Escherichia coli transfected with a modified CYP1A1 cDNA [33, 34] , in the laboratory of H. W.
Strobel (University of Texas, Medical School of Houston, Texas, USA) by P. Hodek (Charles University, Prague, Czech Republic). Rat CYP1A2 was purified to homogeneity from hepatic microsomes of rats treated with β-naphthoflavone as described [35] .
Preparation of antibodies
Leghorn chicken were immunized subcutaneously three times a week with rat recombinant CYP1A1 or rat CYP1A2 antigens (0.1 mg/animal) emulsified in complete Freund's adjuvant for the first injection and in incomplete adjuvant for boosters. Immunoglobulin fraction was purified from pooled egg yolks using fractionation by polyethylene glycol 6000 [33, 34] .
Rabbit polyclonal antibodies against human NQO1 were from Sigma Chemical Co (St Louis, MO, USA).
Estimation of CYP1A1, CYP1A2 and NQO1 protein content in microsomes and cytosols of rat liver, lung and kidney
Immunoquantitation of rat hepatic, pulmonary and renal microsomal CYP1A1, CYP1A2 and of cytosolic NQO1 was done by sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis.
Samples containing 70 µg microsomal or cytosolic proteins were subjected to electrophoresis on SDS/10% polyacrylamide gels [23, 24] . After migration, proteins were transferred onto polyvinylidene difluoride membranes. Rat CYP1A1, CYP1A2 and NQO1 proteins were probed with the chicken polyclonal antibodies raised against CYP1A1 or CYP1A2 and rabbit antibodies against human NQO, respectively, as reported elsewhere [23, 24, 28, 33, 35] . The antibodies against rat CYP1A1 and those against rat CYP1A2 recognize CYP1A1 and CYP1A2 in liver microsomes always as two protein bands, corresponding to CYP1A1 and CYP1A2. The antibodies against human recombinant NQO1 recognize this enzyme in rat hepatic, pulmonary and renal cytosols as indolylphosphate/nitrobluetetrazolium as chromogenic substrate [23, 24, 28, 33, 35] . Band intensities were quantified by Elfoman software.
CYP1A1, CYP1A2 and NQO1 enzyme activity assays
The microsomal samples were characterized for CYP1A1/2 activity using 7-ethoxyresorufin Odeethylation (EROD) activity and for CYP1A2 using 7-methoxyresorufin O-demethylation (MROD) activity [33, 34, 36] . One unit of EROD and MROD activities is defined as the amount of enzyme catalyzing the production of 1 pmol of resorufin in 1 min. The cytosolic samples were characterised for NQO1 activity. NQO1 activity was measured essentially as described by Ernster [37] , but because of low activities of this enzyme in rat cytosolic samples, the method was improved by addition of cytochrome c. The standard assay system contained 25 mM Tris-HCl (pH 
Results
The effect of intratracheal instillation of 3-NBA to rats on expression of enzymes activating 3-
NBA and 3-ABA
In the present study, Western blots using polyclonal antibodies raised against NQO1, CYP1A1
and CYP1A2 showed that the expression of all these enzymes was induced after 2 days in liver, lung and kidney of rats that received 3-NBA by intratracheal instillation (Figs. 2 and 3 ).
The NQO1 protein was expressed in all organs of control (untreated) rats, being highest in the liver; 3.4-and 6.2-fold higher levels were found in liver than in lung and kidney, respectively (Fig. 2) . The levels of NQO1 protein were enhanced in liver after intratracheal instillation of rats with 0.2 or 2 mg 3-NBA/kg bw, by 5.8-and 8.7-fold, respectively (Fig. 2) . The expression of protein of this enzyme was also induced dose-dependently in kidney and lung, but to a lesser extent than in the liver (Fig. 2) . The increased expression of NQO1 in the liver was paralleled by an increased activity of this enzyme ( Table 1) . Because of the low activity of NQO1 in kidney and lung, the effect of treating rats with 3-NBA on NQO1 activity in these organs was not evaluated.
The expression of CYP1A1 and CYP1A2 in microsomes was also induced in rats after intratracheal instillation with 3-NBA. Chicken antibodies raised against rat CYP1A1 or CYP1A2 used in this work each recognized both CYP1A isoforms because of a high degree of homology in their proteins [38] . The efficiency of 3-NBA to induce expression of CYP1A1 was higher than that of CYP1A2 in all organs tested in this study. In lung even no induction of CYP1A2 expression was found at all (Fig. 3) . The EROD and MROD activities, which were used as markers of CYP1A1/2 and CYP1A2 activities, respectively [38] , were induced by 3-NBA in livers (Table 1) . Whereas the increase in EROD activity was much lower than the increase in CYP1A1 expression, induction of MROD closely correlated with the increase in CYP1A2 protein expression in rat liver.
Because of the low basal levels of CYP1A enzymes in kidney and lung, the effect of treating rats with 3-NBA on their activities with EROD and MROD was not determined.
The effect of intratracheal instillation of 3-NBA to rats on activation of 3-NBA by hepatic, pulmonary and renal cytosols and microsomes
Cytosolic samples isolated from liver, kidney and lung of rats 2 days after intratracheal instillation of 3-NBA were capable of reductively activating 3-NBA to species forming a cluster of 5 adducts in calf thymus DNA (see spots 1− − − −5 in Figure 4A for the liver cytosol). Thin-layer chromatograms of In the presence of NADPH, hepatic cytosol from control rats was 2.6-and 4.7-fold more effective to activate 3-NBA than cytosols from kidney and lung, respectively (Fig. 5) . 3-NBA was more effectively activated by cytosols from all organs of rats treated with 3-NBA in a dose dependent manner (Fig. 5) . Up to 8.6-fold higher levels of 3-NBA-derived DNA adducts were found in incubations with hepatic cytosols of rats treated with 2 mg 3-NBA/kg bw relative to those of control rats, whereas only 2.3-and 2-fold higher levels of adducts were found using cytosols of kidney and lung, respectively (Fig. 5) .
Liver microsomes of control rats and those treated with 3-NBA activated 3-NBA. Only a 1.7-fold increase in 3-NBA-derived DNA adduct levels was found in liver microsomes isolated from rats treated with 2 mg 3-NBA/kg bw ( Table 2) . Because CYP1A1/2 were found to also activate 3-NBA [17], this increase is probably caused by induction of these enzymes. No 3-NBA-derived DNA adducts were however detectable after incubating 3-NBA with any of the pulmonary or renal microsomes and NADPH (data not shown). Hence, it seems that the activities of microsomal NADPH:CYP reductase and/or CYP are not sufficient to activate 3-NBA to an extent that DNA adduct formation is detectable in these extrahepatic organs.
The effect of intratracheal instillation of 3-NBA to rats on activation of 3-ABA by rat hepatic, pulmonary and renal microsomes
In the presence of NADPH, rat liver, lung and kidney microsomes were capable of oxidizing 3-ABA to form DNA adducts (see Figure 4B ). Microsomal activation of 3-ABA generated a pattern of DNA adducts consisting of a cluster of five adducts (spots 1-5 in Figure 4B for the liver microsomes). No DNA adducts were generated without NADPH a cofactor of CYP-mediated system, (data not shown). In the presence of NADPH, liver microsomes of control rats 6.4-and 12.4-fold more efficiently activated 3-ABA than microsomes isolated from kidney and lung, respectively (Fig. 6) . Liver, lung and kidney microsomes isolated from rats after intratracheal instillation with 2 mg 3-NBA/kg bw exhibited 3.9-, 9.7-and 3.3-fold higher efficiencies to activate 3-ABA, respectively, than microsomes from control rats (Fig. 6) . Chromatograms of DNA digests from control incubations carried out in parallel without microsomes, without NADPH, without DNA, or without 3-ABA were all devoid of adduct spots in the region of interest (data not shown).
Discussion
The present study has increased our knowledge on the potential of 3-NBA to induce several biotransformation enzymes after intratracheal instillation that are responsible for metabolic activation of this carcinogen (NQO1) and its human metabolite, 3-ABA (CYP1A1/2), in the lung, the target organ for 3-NBA carcinogenicity, in the liver and kidney of rats. The rat was used as an experimental model on the basis that the same enzymes activate 3-NBA and 3-ABA in livers of rat and human [15, 17, 18, 23, 25, 27] . Therefore, the results should provide some indication of what might occur in tissues of humans exposed to this carcinogenic pollutant.
Recently, we have shown that in Wistar rats treated i.p with a single dose of 0.4, 4 or 40 mg/kg bw 3-NBA acts as an inducer of NQO1 and CYP1A1/2 in liver, lung and kidney [23, 24] . This induction was found to lead to an increase in the activities of these enzymes and in their potential to activate 3-NBA in cytosols (NQO1) and 3-ABA in microsomes (CYP1A) to species forming DNA adducts [23, 24] . 3-NBA delivered i.p. is absorbed via the mesenteric veins and lymphatic systems, and passes through the liver. Thus, its concentration and effect in this tissue was higher than in the distal tissues such as lung and kidney (induction of NQO1 and CYP1A1 expression in liver of these rats was up to 5-and 2-fold higher than in lungs and kidneys, respectively) [23, 24] . Since human exposure to 3-NBA occurs primarily via the respiratory tract and inhaled particles, we here evaluated the potential of 3-NBA administered by intratracheal instillation on enzymes capable of reducing 3-NBA or oxidizing 3-ABA. Sprague-Dawley rats were used for this study, because this animal model was successfully utilized to evaluate the long-term persistence of 3-NBA-derived DNA adducts after treatment by instillation [22] . The results of this work show that 3-NBA induces NQO1 and CYP1A1/2 also after intratracheal instillation to rats. The highest increase in expression levels of the enzymes studied was found again in the liver, followed by kidney and lung, with exception of CYP1A1 expression in the kidney. However, expression of this protein in this organ in control rats was hardly detectable by Western blotting, which might overestimate its relative increase after 3-NBA treatment. The increase in expression of CYP1A1/2 and particularly NQO1 in the liver correlated with increased enzymatic activities and the activation of 3-NBA and its metabolite, 3-ABA, by hepatic cytosols and microsomes. The induction of CYP1A1/2 and NQO1 by 3-NBA is probably caused by binding of this planar molecule to the aryl hydrocarbon (Ah) receptor, which is known to be responsible for induction of CYP1A [38, 39] and is one of the mechanisms responsible for induction of NQO1 (see [40] for a review).
The induction of NQO1 and CYP1A1 in the livers by 3-NBA administered by intratracheal instillation was higher than in the liver of rats treated by intraperitoneal injection [23]; a more than one order of magnitude lower 3-NBA dose produced similar expression levels. This finding underlines the risk for humans when exposed to this carcinogenic air pollutant by inhalation. All the more so, if one considers that the influence of 3-NBA instillation on the activation of its metabolite 3-ABA was highest in lungs. Indeed, the levels of 3-ABA-derived DNA adducts generated by lung microsomes isolated from 3-NBA-treated rats were almost 10 times higher than those formed by pulmonary microsomes from controls. This is the highest value of enzyme induction determined in this study.
As it is known that both NQO1 and CYP1A1/2 are expressed in liver, lung and kidney not only in rats but also in humans [35, 40, 42] , these enzymes could contribute significantly and specifically to the metabolic activation of 3-NBA and/or 3-ABA in the human lung, thereby mediating 3-NBA carcinogenicity in this organ.
Inter-individual variations in susceptibility and variations in drug-metabolizing enzyme activities in target tissues appear to be important determinants of cancer risk [41, 42] . Expression levels and activities of NQO1 and CYP1A1/2 differ considerably among individuals, because the enzymes are influenced by several factors, including smoking, drugs and environmental chemicals [38, 41, 43] . It should be noted that besides induction of these enzymes by several compounds are also determined by genetic polymorphisms. Thus, genetic polymorphisms in both enzymes could be important determinants of a possible lung cancer risk from 3-NBA. So far two polymorphisms in the human NQO1 gene have been found in the general population, one of them being associated with an increased risk of urothelial tumours [45] and paediatric leukaemia [46] .
The polymorphic expression of CYP1A1 has been attributed to altered expression of the aryl hydrocarbon (Ah) receptor, the transcription factor that modulates its regulation, or the Ah receptor nuclear translocator (Arnt) protein, its associated transcription factor [40, 44, 47] . Moreover, the CYP1A1 and CYP1A2 genes are polymorphic [38, 42, 48, 49] . So far, CYP1A1*2A, CYP1A1*2B
and CYP1A1*4 polymophisms have been found that might be associated with cancers of lung, oesophagus or breast and with acute myeloid leukaemia [50] [51] [52] [53] , while the CYP1A2*1F polymorphism might be associated with an increased risk of colorectal cancer [48] . In addition, the combination of NAT2 plus CYP1A1*2A, CYP1A1*2C, or CYP1A2*1F genotypes, and that of CYP1A2*1F plus CYP1A2*1C may define a group of persons who are genetically susceptible to colorectal cancer [49] .
In conclusion, the results of the present study show for the first time that 3-NBA is capable of inducing NQO1 and CYP1A1/2 enzymes in rat liver, lung and kidney after intratracheal 
